Nystatin Use in Diabetes: Dosing, Risks, and Clinical Considerations

Dosing Recommendations

The Infectious Diseases Society of America recommends nystatin oral suspension (100,000 U/mL) at 4–6 mL taken four times daily for 7–14 days in patients with diabetes 1.
The same guideline recommends nystatin pastilles (200,000 U each) at 1–2 pastilles taken four times daily for 7–14 days as an alternative formulation 2.
These dosing regimens carry a strong recommendation supported by moderate‑quality evidence 1.

Diabetes is identified as a predisposing factor for oral candidiasis due to immune dysfunction 4.
Patients with type 1 diabetes have heightened susceptibility to oral fungal infections, underscoring the need for appropriate antifungal therapy 4.

Nystatin exhibits negligible systemic absorption, resulting in no known pharmacologic interactions with insulin or other diabetes medications 3.

Clinicians should not withhold nystatin in diabetic patients solely because of diabetes concerns, as there is no pharmacologic basis for such withholding 3.
Treatment failure should be monitored; resistance, particularly in Candida glabrata, can occur and may require alternative strategies 4.
For moderate‑to‑severe oral candidiasis, fluconazole (100–200 mg daily for 7–14 days) is an alternative, but it necessitates closer glucose monitoring because azole agents can affect systemic metabolism [1][2].